trial · primary record
Glofitamab
Non-Hodgkin's Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 940 |
| Primary completion | 2029-03-30 |
| Primary endpoint | Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs) |
| Registry ID | NCT03075696 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:00.158Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03075696
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.